Put companies on watchlist
Galenica AG
ISIN: CH0360674466
WKN: A2DN0K
Curious about what AI knows about Galenica? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Galenica AG · ISIN: CH0360674466 · EQS - Company News (13 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1881579
16 April 2024 06:05PM

Galenica successfully places a bond of over CHF 100 million


Galenica AG / Key word(s): Bond
Galenica successfully places a bond of over CHF 100 million

16.04.2024 / 18:05 CET/CEST


Press release

Today, Galenica successfully placed a fixed rate bond of over CHF 100 million.

The bond has a term of 7 years and an annual coupon of 1.65%. The proceeds from the transaction will be used for general corporate purposes. With this new bond, Galenica is reducing its short-term financial liabilities and securing its long-term financing. The term until 2031 ideally complements the terms of the outstanding bonds from 2026 (CHF 180 million, coupon 1.0%) and 2029 (CHF 240 million, coupon 2.35%).   

 

UBS and Zürcher Kantonalbank are joint lead manager for this issue. An application for admission to trading on the SIX Swiss Exchange for the bond is being made.

Dates for the diary

23 May 2024 Galenica Group sales update
6 August 2024   Galenica Group half-year results 2024
24 October 2024 Galenica Group sales update

 

For further information, please contact:

 

Media Relations:
E-Mail: media@galenica.com
Tel. +41 58 852 85 17
Investor Relations:
E-Mail: investors@galenica.com
Tel. +41 58 852 85 31

Welcome to the Galenica network!
Our ambition is to meet the needs of patients and customers in the Swiss healthcare market in a seamless, efficient and personalised way. To achieve this, we operate the Galenica network with over 20 Business Units, the strongest partners in the Swiss healthcare market. We offer fully integrated solutions both for customers and patients as well as for pharmacies, drugstores, medical practices, hospitals, retirement and nursing homes, home care providers, wholesalers, pharmaceutical companies, health insurance funds and other partners.
Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information concerning Galenica can be found at www.galenica.com.



End of Media Release


Language: English
Company: Galenica AG
Untermattweg 8
3027 Bern
Switzerland
Phone: +41 058 852 81 11
E-mail: info@galenica.com
Internet: https://www.galenica.com
ISIN: CH0360674466
Listed: SIX Swiss Exchange
EQS News ID: 1881579

 
End of News EQS News Service

1881579  16.04.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1881579&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Galenica AG
Smart analysis and research tools can be found here.
MIC: XSWX
Power-Shortcuts

Galenica AG

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.